NMT2: N-Myristoyltransferase 2
A key enzyme in protein myristoylation, implicated in cancer and infectious diseases.
Gene Information Card
| Symbol | NMT2 |
|---|---|
| Full Name | N-myristoyltransferase 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 10p13 |
| NCBI Gene ID | 9397 ncbi.nlm.nih.gov/gene/9397 |
| Ensembl ID | ENSG00000119912 |
| UniProt ID | O60551 |
| OMIM ID | 603301 |
| HGNC ID | 7858 |
| Aliases | NMT2, NMT-2, NMT2A, NMT2B |
Description
NMT2 encodes N-myristoyltransferase 2, an enzyme that catalyzes the covalent attachment of myristate to the N-terminal glycine residue of target proteins. This modification is essential for membrane targeting, protein-protein interactions, and signal transduction. NMT2 is ubiquitously expressed and plays roles in cellular growth, differentiation, and apoptosis. Dysregulation is linked to various cancers and infectious diseases.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Overexpression of NMT2 promotes cell proliferation and invasion via myristoylation of oncogenic proteins. | PMID: 23455478 |
| Breast cancer | NMT2 upregulation correlates with poor prognosis and enhanced tumor growth. | PMID: 25642768 |
| HIV/AIDS | NMT2 myristoylates HIV-1 Gag polyprotein, essential for viral assembly and infectivity. | PMID: 10601273 |
| Leishmaniasis | NMT2 is a validated drug target in Leishmania species; inhibition blocks parasite growth. | PMID: 15075227 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.3 | Medium |
| Heart | 8.7 | Low |
| Liver | 15.6 | High |
| Kidney | 10.2 | Medium |
| Lung | 9.1 | Low |
| Colon | 18.4 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 14.5 | Cervical cancer cell line |
| HEK293 | 11.2 | Embryonic kidney cells |
| HepG2 | 16.8 | Hepatocellular carcinoma |
| MCF7 | 13.1 | Breast cancer cell line |
| A549 | 9.9 | Lung carcinoma |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.101C>T (p.Thr34Met) | Missense | 0.01% | Unknown functional impact |
| c.452G>A (p.Arg151His) | Missense | 0.005% | Reduced enzyme activity in vitro |
| c.788_789del (p.Leu263fs) | Frameshift | <0.001% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations (e.g., p.Leu263fs) lead to truncated, non-functional protein.
Gain of Function (GOF)
Not reported in NMT2.
Dominant Negative (DN)
Not reported in NMT2.
View complete mutation data：
Gene Ontology (GO)
| • glycylpeptide N-tetradecanoyltransferase activity (GO:0004370) | • N-terminal protein myristoylation (GO:0006499) |
| • cytoplasm (GO:0005737) | • cytosol (GO:0005829) |
| • membrane (GO:0016020) |
Pathways
• Protein myristoylation (R-HSA-163125)
• Myristoylation of HIV-1 Gag (R-HSA-162587)
Protein Summary
NMT2 is a 496-amino acid cytosolic enzyme that transfers myristate from myristoyl-CoA to the N-terminal glycine of substrate proteins. It contains a conserved catalytic domain and is essential for the function of numerous signaling and structural proteins. NMT2 is a target for anticancer and antiparasitic drug development.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NMT2 Knockout HEK293 Cell Line | EDJ-KQ1950 | Human | 9397 | Details Get a Quote |
| NMT2 Knockout A-549 Cell Line | EDJ-KQ21896 | Human | 9397 | Details Get a Quote |
| NMT2 Knockout HCT 116 Cell Line | EDJ-KQ21897 | Human | 9397 | Details Get a Quote |
| NMT2 Knockout HeLa Cell Line | EDJ-KQ21898 | Human | 9397 | Details Get a Quote |
